Hypothesis:~AZVUDINE has a therapeutic potential and safety profile for the treatment of patients infected with SARS-CoV-2.~Goals:~Main goal:~To evaluate the efficacy and safety of AZVUDINE (FNC) in patients infected with SARS-COV-2, in a mild stage;~Specific objective:~To assess the clinical outcome of mild-stage SARS-CoV-2 infected participants treated with AZVUDINE (FNC) versus placebo~Statistical planning:~Statistical description: all statistical tests are performed by bilateral testing. A significance level of 5% will be adopted.~Baseline analysis: including subject distribution, data demographics, and baseline analysis.
Phase III, single-center with co-participating units, randomized, double-blind, parallel, placebo-controlled clinical study